Escitalopram

Pregnancy

Birth defects and miscarriage: MotherToBaby reports that most studies of citalopram or escitalopram have not found more birth defects, while some suggested heart or other defects but had limitations. Klieger-Grossmann et al. (2012) compared 212 escitalopram exposures with 212 other-antidepressant exposures and 212 nonteratogenic-exposure controls. The escitalopram group had 3 major malformations (1.7%) and 15% spontaneous abortions, compared with 8.5% in controls; the miscarriage difference was not statistically significant (P=.066). Huybrechts et al. (2014) studied 949,504 pregnancies; after restricting to women with depression and adjusting for confounders, the SSRI relative risk for any cardiac defect was 1.06 (95% CI 0.93-1.22). Jordan et al. (2016) linked 519,117 deliveries in three EUROCAT regions and found a class-wide severe congenital-heart-defect prevalence of 0.26% versus 0.17% for prescriptions in the 91 days around the last menstrual period (OR 1.50, 95% CI 1.06-2.11); all major anomalies combined were not statistically significant (OR 1.09, 95% CI 0.99-1.21). Wang et al. (2015) pooled four cohort studies with 1,996,519 participants and found no significant association with heart defects (RR 1.06, 95% CI 0.94-1.18). These studies are observational, often class-wide, and do not establish an escitalopram-specific cause. MotherToBaby reports associations between use throughout pregnancy and preterm birth or low birth weight, while noting depression and other factors may contribute. Klieger-Grossmann et al. found lower overall birth weight and increased low birth weight (P=.009), but its small sample does not resolve causation. Late-pregnancy PPHN evidence differs: Chambers et al. (2006) reported an adjusted OR of 6.1 (95% CI 2.2-16.8) in a case-control study with 377 cases and 836 controls; Huybrechts et al. (2015) studied 3,789,330 pregnancies and found an adjusted SSRI OR of 1.10 (95% CI 0.94-1.29) after restricting to women with depression, with an OR of 1.28 (95% CI 1.01-1.64) for primary PPHN. The latter study reported 31.5 PPHN cases per 10,000 SSRI-exposed births and 20.8 per 10,000 unexposed births before adjustment; these are class-wide rates, not escitalopram-specific estimates. Palmsten et al. (2013) studied 106,000 pregnant people with mood or anxiety disorders. Postpartum haemorrhage occurred in 2.8% of those with no antidepressant exposure and 4.0% of current serotonin-reuptake-inhibitor users; current SSRI monotherapy was associated with a relative risk of 1.42 (95% CI 1.27-1.57). The Lexapro label and MHRA notice describe a less-than-twofold increase associated with exposure in the month before delivery. The MHRA notice was published in 2021, outside the five-year audit window, but the current label retains this warning. The Sept 2022 EMA PRAC meeting list included a pulmonary-hypertension signal for SSRIs including escitalopram and recorded routine pharmacovigilance; it did not specify PPHN or a product-information change. Cohen et al. (2006) followed 201 pregnant women with prior major depression; relapse occurred in 26% of those who continued medication and 68% of those who discontinued. This was a naturalistic cohort, not an escitalopram-only trial. The 2025 Choi PBPK model predicted declining escitalopram concentrations with advancing gestation; it modeled exposure and did not measure pregnancy outcomes.

Breastfeeding

LactMed reports low milk levels and advises monitoring for excess drowsiness, restlessness, agitation, poor feeding, and poor weight gain, especially in younger, exclusively breastfed infants. MotherToBaby reports small amounts in milk, a few case reports of infant sleepiness or weight loss, and no harmful effects in most studies. Rampono et al. (2006) measured milk and infant exposure in eight mothers; five infants had serum testing. The abstract reported a total relative infant dose of escitalopram plus metabolite of 5.3% (95% CI 4.2-6.4), and no adverse effects were seen in the small group. The DailyMed label gives 3.9% for escitalopram and 1.7% for the metabolite from the same eight-mother study; the difference from the abstract total was not reconciled and no percentage is used in the summary. Heinonen et al. (2025) studied 97 mother-child pairs, including 22 children exposed to SSRIs through breastfeeding; adjusted IQ scores did not differ between breastfed children with and without postnatal SSRI exposure. The study did not measure outcomes beyond IQ, was not escitalopram-specific, and its pregnancy data were collected earlier. A 2025 lactation PBPK study evaluated model predictions against reported milk concentrations; it predicted exposure and did not measure infant health outcomes.

What was tested

Pregnancy evidence includes prospective and population-based cohorts, case-control studies, linked birth-defect registries, and meta-analysis. The studies are observational and may be affected by the underlying depression and other differences between groups; no randomized trial tests pregnancy outcomes. New 2025 pregnancy PBPK work models maternal and fetal drug concentrations rather than birth outcomes. Lactation evidence includes small milk and infant-serum studies, a small clinical follow-up, a 2025 cohort that measured IQ at ages 4 to 5 years, and a PBPK model that predicts milk exposure rather than infant health outcomes.